Cargando…
Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients
Vulnerable patients such as immunosuppressed or elderly patients are at high risk for a severe course of COVID-19 upon SARS-CoV-2 infection. Immunotherapy with SARS-CoV-2 specific monoclonal antibodies (mAb) or convalescent plasma represents a considerable treatment option to protect these patients...
Autores principales: | Thümmler, Laura, Lindemann, Monika, Horn, Peter A., Lenz, Veronika, Konik, Margarethe, Gäckler, Anja, Boss, Kristina, Theodoropoulos, Fotis, Besa, Vasiliki, Taube, Christian, Brenner, Thorsten, Witzke, Oliver, Krawczyk, Adalbert, Rohn, Hana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861454/ https://www.ncbi.nlm.nih.gov/pubmed/36680159 http://dx.doi.org/10.3390/v15010119 |
Ejemplares similares
-
Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment
por: Thümmler, Laura, et al.
Publicado: (2022) -
SARS‐CoV‐2‐specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma
por: Lindemann, Monika, et al.
Publicado: (2021) -
Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age
por: Konik, Margarethe, et al.
Publicado: (2021) -
Peripheral HLA-G/ILT-2 immune checkpoint axis in acute and convalescent COVID-19 patients
por: Rohn, Hana, et al.
Publicado: (2023) -
Cellular and Humoral Immunity against Different SARS-CoV-2 Variants Is Detectable but Reduced in Vaccinated Kidney Transplant Patients
por: Thümmler, Laura, et al.
Publicado: (2022)